- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07669220
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) (STAR)
21 juni 2026 bijgewerkt door: Sixth Affiliated Hospital, Sun Yat-sen University
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk locally advanced pMMR/MSS lower rectal adenocarcinoma, aiming to provide high-level evidence supporting a novel treatment paradigm.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
76
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Guangzhou, China
- Werving
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Contact:
- YiFeng Zou
- Telefoonnummer: 13719225862
- E-mail: zouyif@mail.sysu.edu.cn
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Before implementing any procedures related to the study protocol rather than routine clinical care, a signed and dated informed consent form must be obtained from the subject voluntarily, in accordance with regulatory requirements and institutional guidelines.
- Age 18-75 years.
- Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma.
- The lower edge of the rectal tumor is located below the peritoneal reflection.
- Locally advanced disease with high-risk factors, meeting at least one of the following: cT4 / cN2 / EMVI+ / MRF+ / positive lateral lymph node.
- No clear evidence of distant metastasis prior to treatment.
- No prior anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
- ECOG performance status 0-1 (Appendix 1).
Peripheral blood counts and liver and renal function within the following ranges (tested within 15 days before treatment initiation):
White blood cell count (WBC) ≥ 3.0 × 10⁹/L or absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
- Hemoglobin (HGB) ≥ 80 g/L; ③ Platelet count (PLT) ≥ 100 × 10⁹/L; ④ Hepatic transaminases (AST/ALT) < 3.0 × upper limit of normal (ULN); ⑤ Total bilirubin (TBIL) < 1.5 × ULN; ⑥ Creatinine (CREAT) < 1.5 × ULN.
- No history of other concurrent malignancies; not pregnant or lactating; effective contraceptive methods should be used during the study period and for 6 months after the last dose.
Exclusion Criteria:
- Patients with a history of severe drug allergy (including allergy to platinum agents, 5-FU, and 5-HT3 receptor antagonists).
- Patients who have participated in or are currently participating in another clinical trial within 4 weeks prior to enrollment.
- History of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or any other therapy specifically targeting T-cell co-stimulation or checkpoint pathways.
- Severe electrolyte abnormalities.
- Presence of gastrointestinal diseases such as active gastric or duodenal ulcer, ulcerative colitis, or unresected tumor with active bleeding; or other conditions that may cause gastrointestinal bleeding or perforation; or unhealed gastrointestinal perforation after surgical treatment.
- History of arterial thrombosis or deep vein thrombosis within 6 months; evidence of bleeding tendency or hemorrhagic history within 2 months; currently receiving high-dose anticoagulation therapy.
- Pregnant or lactating women, or women of childbearing potential with a positive pregnancy test prior to the first dose; or female participants and their partners who are unwilling to practice strict contraception during the study period.
- Presence of other concurrent or prior active malignancies (except for malignancies that have been curatively treated with no recurrence for more than 3 years, or carcinoma in situ that can be cured by adequate treatment).
- Severe electrocardiogram abnormalities, or active coronary artery disease, severe/unstable angina, newly diagnosed angina or myocardial infarction within 12 months prior to study entry, or congestive heart failure of NYHA Class II or higher.
- Patients with active infection (infection causing fever > 38°C).
- Patients with poorly controlled hypercalcemia, hypertension, or diabetes mellitus.
- Patients with severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.).
- Patients with mental disorders affecting clinical treatment or a history of central nervous system disease.
- Patients with severe complications (intestinal obstruction, renal insufficiency, hepatic insufficiency, cerebrovascular disorders, etc.).
- Presence of any unresolved toxicity of CTCAE Grade 2 or higher resulting from prior therapy (except for anemia, alopecia, and skin pigmentation).
- Any medical condition that is unstable or may affect patient safety and compliance with the study.
- Patients deemed by the investigator to be unsuitable for participation in this clinical trial.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: SCRT-PD1-FOLFOX
|
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
|
|
Actieve vergelijker: LCRT-FOLFOX
|
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
CCR
Tijdsspanne: 3 years
|
cCR+pCR
|
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
3-year RFS
Tijdsspanne: 3 years
|
3 years
|
|
3-year DFS
Tijdsspanne: 3 years
|
3 years
|
|
3-year OS
Tijdsspanne: 3 years
|
3 years
|
|
3-year DMFS
Tijdsspanne: 3 years
|
3 years
|
|
R0 Resection Rate
Tijdsspanne: 3 years
|
3 years
|
|
MPR Rate
Tijdsspanne: 3 years
|
3 years
|
|
Treatment-Related Adverse Events / Treatment Toxicity
Tijdsspanne: 3 years
|
3 years
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 januari 2026
Primaire voltooiing (Geschat)
1 januari 2028
Studie voltooiing (Geschat)
1 januari 2028
Studieregistratiedata
Eerst ingediend
21 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
21 juni 2026
Eerst geplaatst (Werkelijk)
25 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
25 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
21 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026ZSLYEC-285
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
ONBESLIST
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .